WO2023007472 - ANTI-CD36 ANTIBODIES AND THEIR USE TO TREAT CANCER
National phase entry:
Publication Number
WO/2023/007472
Publication Date
02.02.2023
International Application No.
PCT/IB2022/057098
International Filing Date
29.07.2022
Title **
[English]
ANTI-CD36 ANTIBODIES AND THEIR USE TO TREAT CANCER
[French]
ANTICORPS ANTI-CD36 ET LEUR UTILISATION POUR TRAITER LE CANCER
Applicants **
ONA THERAPEUTICS S.L.
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
Inventors
AZNAR BENITAH, Salvador
c/o ONA THEAPEURICS
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
VANHOOREN, Valerie
c/o ONA THEAPEURICS
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
DE FRIAS SÁNCHEZ, Mercè
c/o ONA THEAPEURICS
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
MORANCHO ARMISEN, Beatriz
c/o ONA THEAPEURICS
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
GUARDIOLA BAGÁN, Salvador
c/o ONA THEAPEURICS
Carrer Baldiri Reixac 10 (No. 4-8)
08028 Barcelona, ES
GEOFFREY, Hale
c/o MABSOLVE LIMITED
The Wheelhouse, Angel Court,
81 St Clements St.
Oxford OX4 1AW, GB
WILKINSON, Ian
c/o MABSOLVE LIMITED
The Wheelhouse, Angel Court,
81 St Clements St.
Oxford OX4 1AW, GB
Priority Data
63/227,806
30.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 7657 | |
| EPO | Filing, Examination | 144050 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 50510 |
Total: 203378 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The claimed invention relates to treating cancer by targeting CD36, a fatty acid receptor. The claimed invention also relates to treating cancer metastases by targeting CD36. The invention involves using anti-CD36 antibodies as blockers or inhibitors of CD36 activity to treat or prevent cancer and/or metastatic cancer in a subject.[French]
L'invention concerne le traitement du cancer par ciblage de CD36, un récepteur d'acide gras. L'invention concerne également le traitement de métastases cancéreuses par ciblage de CD36. L'invention implique l'utilisation d'anticorps anti-CD36 en tant que bloqueurs ou inhibiteurs de l'activité de CD36 pour traiter ou prévenir le cancer et/ou le cancer métastatique chez un sujet.